Objective: The intravesical instillation of bladder cocktails via catheter is a widely spread, most effective way of treatment of interstitial cystitis/bladder pain syndrome. This disease often affects the urethra too, causing tenderness and pain. Therefore, catheterization causing superficial mucosal lesions triggers strong and long-lasting pain, sometimes bleeding, and a higher risk of infection. Methods: We invented an adapter fitting on both Luer-lock and Luer-slip syringes allowing the injection of "bladder cocktails" into the bladder through the urethra in a retrograde way; the injected fluid opens the bladder sphincter. Its radiused tip and the specially shaped flexible isolating collar allow us to perform drop-free instillation without catheterization. In the last 2 years, clinical evaluations were conducted in 270 interstitial cystitis/bladder pain syndrome patients (243 female, 27 male), altogether totalling 1520 instillations. Results: In 5 of 243 female patients (2%) using the syringe adapter was unsuccessful due to the deep located urethral orifice or cicatricose vaginal opening. This made visualization of the urethral orifice impossible (success rate: 98%). All the 27 male patients (100%) could be treated without any difficulties. No infection due to the instillation was observed. All treatable patients preferred the catheter-free method to conventional catheterization. They did not report any pain, long-lasting burning sensation or any other complications.
Introduction
Local instillation therapy of the bladder is a generally accepted and widely used treatment modality of the bladder in different pathological conditions. Its advantages are the locally high concentration of the active drug and the reduced level of systemic side effects. 1 Intravesical instillation therapy is at present most frequently applied in cases of superficial bladder cancer to reduce the rate of local recurrence, 2 and in the treatment of IC/BPS. 3, 4 Intravesical drug delivery has also been reported to be efficacious in chronic bacteriological bladder infections, 5 refractory overactive bladder, 6 and following pelvic radiotherapy. 7 The widely spread and generally accepted method of bladder instillation is the unconditional use of a urethral catheter. Any catheterization carries the risk of the known side effects of micro-or macroscopic lesions of the urethral mucosa, and as a consequence, also pain, bleeding, and a higher risk of infection. 8 Approximately 70% of IC/BPS patients report hypersensitivity or even actual pain inside the urethra. In these patients, urethral catheterization can trigger very severe pain and a longlasting flare-up of their symptoms. These significant side effects are intolerable for many patients, leading them to refuse the offered instillation therapy.
Methods
We invented a urological syringe adapter, which allows us to inject "bladder cocktails" through the urethral orifice into the empty bladder in a retrograde way -without the need for urethral catheterization.
The adapter consists of four main parts ( Fig. 1 ):
• The radiused, atraumatic short tip, which intrudes just a few millimeters into the urethral orifice. The elastic, concave isolating collar, which fits over the surrounding surface of the external urethral orifice, creates a closed space and thereby enables leakage-free instillation to be performed
• The median part, which serves to safely grasp and place the adapter onto the syringe
• The connecting tail fitting on both Luer-slip and Luer-lock syringes ( Fig. 2) We used the adapter in IC/BPS patients for intravesical GAG layer replenishment therapy in both genders. 243 female and 27 male patients received instillations, altogether totalling 1520 times.
The method of use was basically identical in both genders. We place the adapter onto the syringe with some rotating force to fix it. Following thorough disinfection of the urethral orifice and its close neighborhood, we insert the tip-part of the adapter into the orifice and press the syringe against it with gentle pressure to allow the elastic isolating collar achieve full contact with the periurethral mucosa. Then slowly instill the drug solution through the urethra into the bladder (Figs 3 and 4) .
We evaluated the level of inconvenience, the complication rate, and the patients' acceptance based on the patients' selfreported observations.
Results
We were able to instill the bladder cocktail in 238/243 female patients (success rate 98%) without any difficulties or significant leakage. The instillation failed in 5/243 patients (2%) due to very narrow, cicatricose vaginal opening (3 patients) because the isolating collar could not be passed through the 
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Editorial material and organization © 2019 The Japanese Urological Association. Copyright of individual abstracts remains with the authors. vaginal introitus. In 2 patients the extremely deeply located urethral orifice inhibited drop-free instillation as the isolating collar could not fit over the inclined periurethral surface. These situations also made reliable visualization of the urethral orifice impossible.
All the 27 male patients (100%) could be treated without any difficulties.
There was no post-treatment bacteriological infection observed related to the instillation.
The acceptance rate of the new catheter-free method was 100%. All treated patients preferred the catheter-free method to conventional catheterization. None of them would ever consider being catheterized any more.
No patient reported any pain, long-lasting burning sensation or any other complications.
Discussion
Most patients are afraid of being catheterized because of the pain in the urethra associated with this procedure. This pain is partially due to the tenderness caused by inflammatory processes in the urethra and also to the inevitably occurring microscopic mechanical superficial mucosa lesions. Sometimes (mostly in male patients) the lesions can hurt even deeper layers of the urethra and result in more expressed and long-lasting pain or urethral bleeding. In IC/BPS especially, the urethra is in 70% of the patients hypersensitive or explicitly painful due to the inflamed urethral mucosa caused by continuous, long-lasting chemical irritation of the urine.
The presented novel syringe adapter means that patients no longer have to be subjected to painful and invasive urethral catheterization. By using the novel, catheter-free instillation method, no mechanical injury can occur as only the liquid drug solution flows through the urethra into the bladder. In this way, the procedure becomes minimally invasive and therefore completely painless.
There is an additional, significant advantage to be mentioned: a small proportion of the instilled drug solution stays over the surface of the urethra in an undiluted concentration, until the first spontaneous urination. In this way, the urethral surface and bladder mucosa can be treated simultaneously. Recommending patients to reduce liquid consumption before the procedure and by instilling local anesthetics (10 mL 2% Lidocaine hydrochloride solution) before instillation of the "cocktail" makes patients capable of holding the drug solution inside the bladder for 2-3 times longer. This longer impact could theoretically improve the efficacy of the treatment, although not yet proven in clinical trials.
After complete emptying of the bladder by spontaneous urination, we check if the bladder is empty by suprapubic ultrasound examination. If there is significant residual urine (approx. <40 mL), it is a contraindication of using the catheter-free method of instillation, as residual urine would dilute instilled drug solution to such a great extent that its efficacy would be greatly reduced or it could even become completely ineffective.
The adapter underwent six development phases in the last 3 years until we found the optimal form and the best biocompatible semirigid plastic material (Fig. 1) .
The main goal during the catheter-free instillation is that the fluid is able to open the bladder sphincter while not allowing the liquid to leak, i.e., to eliminate leakage of the instilled drug solution. The specially shaped, concave and flexible isolating collar has been developed to do this, to ensure drop-free instillation.
After the radiused short tip is placed into the urethral orifice, the adapter should first be pressed against the orifice with continuous gentle pressure. In this way the isolating collar fits over the peri-urethral mucosa with its whole surface forming a closed space together with the syringe. Insufficient strength of pressure causes leakage. Thus, an uncontrolled portion of the solution may flow down into the vagina, from where it leaks out as the patient stands up.
Contrary to this, too strong pressure causes the urethra to be kinked, which makes the urethra completely impassable, and the whole amount of instilled solution can therefore enter the vagina. Fortunately, the sterile, tissue-friendly solution does not cause any harm to the vagina, but naturally reduces the intravesical efficacy.
Finding the right vertical angle of the urethral axis plays a determining role in successful instillation. In most cases, starting the procedure horizontally straight causes the urethra to be pressed against the lower edge of the symphysis, thus making the urethra impassable. Therefore, we should start leading the adapter at a 45-degree downwards, and in this way by-passing the symphysis from below, we target the bladder with the direction. We then still need to seek the appropriate angle of the syringe by lowering or elevating its distal end. We can sense whether we have reached the right angle by the resistance of the easily movable syringe piston. The resistance suddenly reduces as soon as the right angle is achieved.
This catheter-free instillation is the choice of method in male patients, too. It is even easier to perform instillation in these patients than in female patients.
It is important to ask the patient to relax when we start to inject the solution. Relaxation reduces the tone of the external sphincter and indirectly also the intraurethral pressure. Deep breathing can help the patient to relax the sphincter. If the patient is not able to relax or we instill the drug solution too quickly, intraurethral pressure can reach undesirable and uncontrolled high pressure causing pain or even mucosal bleeding. Therefore, the injection should be made slowly, while the patient should be repeatedly asked to relax. If growing resistance can be felt by pushing the piston or the patient gives signs of pain, the injection should be stopped temporarily and just slowly continued when the pain disappears and the resistance is reduced due to relaxation.
Male patients are more prone to experience this problem because their double sphincter causes a higher level of the retrograde sphincter opening pressure (50-60 cm H 2 O vs 25-30 cm H 2 O in females). In both genders, the drug solution should be slowly injected into the urethra. As soon as the slowly elevating intraurethral pressure reaches the level of sphincter opening, the solution flows into the bladder, but some proportion of it remains inside the urethra. In female patients, this amount of drug solution is insignificant, but in males, the residual amount inside the urethra is about 10-15 mL depending on individual anatomical variations. In order not to waste this volume, 15 mL air is pumped with the syringe into the urethra which pushes the residual solution into the bladder, and just a thin film of the drug remains attached to the surface of the urethra.
There are just a few contraindications for catheter-free instillation using the syringe adapter. All circumstances which make urethral orifice invisible can inhibit drop-free instillation. In female patients: a deep orifice, opening on the vaginal wall and/or very narrow vaginal introitus mostly in sexually inactive, elderly patients. In males: most cases of hypo-and epispadias, expressed stricture of the meatus or pinpoint phimosis.
Like all instrumental or surgical interventions, catheter-free instillation naturally also needs some skill. But the learning curve of the therapists is quite short; in male patients 3-6 instillations, whereas in female patients 15-20 instillations can be necessary to reach the appropriate level.
The vast majority of our cases were IC/BPS patients, but there are other indications too where catheter-free instillation proves to have advantages. These include the rapidly growing number of patients with radiotherapy-induced cystitis and the cytostatic drugs-and BCG-induced cases of chemo-cystitis, chronic or frequently recurring bacterial cystitis, therapyresistant overactive bladder, all for therapeutic purposes. In the field of diagnostics, the syringe adapter can be used to perform retrograde urethrography or fistulographies.
Conclusion
The new non-invasive instillation method replaces urethral catheterization in all cases where local, intravesical drug delivery is indicated. It is minimally invasive, does not hurt the urethral mucosa, and is therefore a completely pain-free procedure. It is the only available way of treating the bladder and urethral mucosa simultaneously. It reduces pain and the complication rate compared to conventional catheterization and at the same time reduces time, costs and inconvenience of bladder instillation. All these advantages improve the quality of life significantly and allow local instillation therapy for the bladder to become accessible for the wider population.
Due to high patient compliance and acceptance of the catheter-free instillation method, we can expect rapid growth in the number of treatments worldwide.
